Journal
SCIENCE
Volume 328, Issue 5980, Pages 852-856Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1184784
Keywords
-
Categories
Funding
- NIH [AI067027, AI057086, AI080651, HL055936, HL100928, AI50732, HL71241, HL092883, HL075845]
- NIAID, NIH
- Bill and Melinda Gates Foundation
Ask authors/readers for more resources
Mycobacterium tuberculosis has a penetrance of its host population that would be the envy of most human pathogens. About one-third of the human population would have a positive skin test for the infection and is thus thought to harbor the bacterium. Globally, 22 high-burden countries account for more than 80% of the active tuberculosis cases in the world, which shows the inequitable distribution of the disease. There is no effective vaccine against infection, and current drug therapies are fraught with problems, predominantly because of the protracted nature of the treatment and the increasing occurrence of drug resistance. Here we focus on the biology of the host-pathogen interaction and discuss new and evolving strategies for intervention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available